We are live on ! Find out more
ARLZ

Aralez Pharmaceuticals Inc.
ARLZ

Delisted

ARLZ was delisted on the 20th of August, 2018.

Back to rankings

1 hedge funds and large institutions have $0 invested in Aralez Pharmaceuticals Inc. in 2018 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% less funds holding

Funds holding: 4 → 1 (-3)

100% less capital invested

Capital invested by funds: $1K → $0 (-$1K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-3
Holders Change %
-75%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

ARLZ Hedge Fund Activity: Q4 2018 in Review

1 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Aralez Pharmaceuticals Inc. (ARLZ) for Q4 2018, worth a combined $0 — down 100% from $1K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ARLZ and 0 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 0 added.

  • 1 institutional investor held Aralez Pharmaceuticals Inc. (ARLZ) as of Q4 2018, down from 4 in Q3 2018.
  • Funds reported $0 of Aralez Pharmaceuticals Inc. stock for Q4 2018, down 100% quarter-over-quarter.
  • 0 funds opened new Aralez Pharmaceuticals Inc. positions in Q4 2018 and 3 closed out, a net change of -3 holders.

Based on aggregated 13F filings for Q4 2018.